Delayed Ejaculation in Men: Causes, Mechanisms, and Treatment

Delayed ejaculation (DE) is the least studied and least understood of the male ejaculatory disorders. While premature ejaculation receives substantially more research attention, delayed ejaculation presents distinct diagnostic and treatment challenges. In severe cases it becomes anejaculation — the inability to ejaculate at all — despite normal erection and arousal.

Definition and Classification

Delayed ejaculation is defined as a persistent or recurrent delay in, or absence of, ejaculation following adequate sexual stimulation and arousal, causing personal distress. [^waldinger2009]

The classification matters for treatment:

Lifelong vs acquired: Lifelong DE has been present since sexual maturity (onset); acquired DE develops after a period of normal ejaculatory function. Lifelong DE often has a neurobiological or constitutional basis; acquired DE more commonly reflects medication effects, injury, or psychological change.

Generalized vs situational: Generalized DE occurs in all sexual contexts. Situational DE occurs in specific contexts only — for example, inability to ejaculate with a partner but normal ejaculation with masturbation. Situational DE strongly suggests a psychosexual etiology rather than neurological or pharmacological cause.

Ejaculation vs orgasm distinction: Some men with DE experience orgasm (subjective climax) without ejaculation. Others have neither. This distinction has diagnostic implications — orgasm without ejaculation suggests retrograde ejaculation or ejaculatory duct obstruction rather than failure of the orgasmic mechanism itself.

Prevalence

DE is the least common of the major male sexual dysfunctions, with prevalence estimates of 1–4% in the general male population. [^laumann1999] However, it is substantially more common in specific populations — particularly men on antidepressants (see below), where prevalence may exceed 30–40% in some drug classes.

The Ejaculatory Mechanism

To understand DE, the normal ejaculatory mechanism must be established.

Ejaculation has two phases coordinated by the spinal cord at T10–L2 (sympathetic) and S2–S4 (somatic):

Emission phase: Sympathetic discharge from the superior hypogastric plexus causes peristaltic contraction of the vas deferens, seminal vesicles, and prostate, depositing seminal fluid into the posterior urethra. Simultaneous bladder neck closure prevents retrograde flow. This phase is involuntary and mediated by the hypogastric nerve. [^giuliano2011]

Expulsion phase: Rhythmic contraction of the bulbospongiosus and ischiocavernosus muscles (pudendal nerve, S2–S4) at 0.8-second intervals propels semen through the urethra. This phase is partly reflex, partly mediated by a lumbar spinal generator (the spinal ejaculation generator or SEG) at L3–L4 in rodent models, likely analogous in humans.

The ejaculatory threshold: Ejaculation requires sufficient afferent sensory input to exceed a central threshold. Input arrives primarily via the dorsal nerve of the penis (pudendal nerve) from the glans and penile shaft. The threshold is regulated by serotonin (inhibitory — higher serotonin raises the threshold), dopamine (facilitory — dopamine lowers the threshold), and oxytocin. [^rowland2010]

This threshold model explains most causes of DE: anything that raises the ejaculatory threshold or reduces sensory input can cause delayed or absent ejaculation.

Causes

Pharmacological (Most Common Acquired Cause)

SSRIs and SNRIs: The most common cause of acquired DE. Serotonin reuptake inhibitors raise central serotonergic tone, which directly raises the ejaculatory threshold. All SSRIs cause ejaculatory delay; the magnitude varies by drug. Paroxetine has the strongest effect; fluoxetine and sertraline are intermediate; escitalopram is generally milder. [^waldinger2009]

This effect is strong enough that SSRIs (particularly dapoxetine, a short-acting SSRI) are used therapeutically for premature ejaculation — the ejaculatory delay is the therapeutic mechanism for PE but becomes a side effect when the drug is used for other indications.

Antipsychotics: Dopamine D2 receptor blockade impairs the dopaminergic facilitation of ejaculation. Thioridazine, risperidone, and haloperidol have particularly significant ejaculatory effects. The mechanism is central dopamine antagonism at the spinal ejaculation generator. [^richardson2006]

Alpha-blockers: Alpha-1A adrenoceptor antagonists (tamsulosin, silodosin) used for BPH block sympathetic emission by preventing smooth muscle contraction in the vas deferens and seminal vesicles. The result is anejaculation or retrograde ejaculation rather than true DE — orgasm occurs but ejaculate is absent. Silodosin has the highest rate (~30%); tamsulosin somewhat lower.

Opioids: Chronic opioid use suppresses testosterone (through hypothalamic-pituitary axis suppression) and may have direct effects on central ejaculatory circuits. Opioid-induced androgen deficiency contributes to ejaculatory dysfunction as well as reduced libido.

Alcohol (acute high doses): Acute alcohol intoxication delays ejaculation through central nervous system depression. Chronic alcohol use causes testosterone suppression and peripheral neuropathy affecting sensory pathways.

Neurological

Spinal cord injury: Lesions at T10–L2 (sympathetic center) affect emission; lesions at S2–S4 affect expulsion. Complete lesions at either level cause anejaculation. Incomplete lesions cause variable DE. Vibro-stimulation (a penile vibrator applied to the frenulum/glans) can trigger reflex ejaculation via the sacral ejaculatory reflex in men with incomplete spinal cord injury. [^giuliano2011]

Diabetic neuropathy: Autonomic neuropathy from long-standing diabetes affects sympathetic fibers mediating emission. Ejaculatory dysfunction (including retrograde ejaculation and DE) is common in men with diabetic autonomic neuropathy.

Pelvic surgery: Radical prostatectomy, abdominoperineal resection, aortoiliac surgery, and bladder surgery can damage the hypogastric plexus, superior hypogastric plexus, or pelvic nerves, causing anejaculation or DE. Nerve-sparing surgical technique reduces but does not eliminate this risk.

Multiple sclerosis: MS lesions in the spinal cord can affect any level of ejaculatory coordination. DE and anejaculation are reported in 30–50% of men with MS.

Psychological and Psychosexual

Psychological factors are the most common identifiable cause of situational DE (present with partner but not during masturbation). [^perelman2006]

Idiosyncratic masturbation patterns: Perelman's concept of "autosexual orientation" describes men who have established a masturbation technique (pressure, rhythm, speed, fantasy) that is highly specific and difficult to replicate with a partner. If the threshold for ejaculation has been calibrated to a very specific input, partner sexual activity may provide insufficient stimulation to cross it. This is the most common psychosexual cause identified in clinical practice.

Performance anxiety: Anxiety about ejaculation can create a self-reinforcing loop. The monitoring of ejaculatory response ("spectatoring") activates sympathetic arousal, which paradoxically inhibits ejaculation (ejaculation requires a transition from sympathetic to parasympathetic balance, similar to the mechanism that inhibits erection under excessive anxiety).

Relationship factors: Ambivalence about the partner, unresolved conflict, or fear of impregnation can manifest as unconscious inhibition of ejaculation. This is more speculative in individual cases but supported by the observation that DE often resolves after relationship change.

Depression: Anhedonia and reduced arousal associated with depression reduce the drive input into the ejaculatory circuit below threshold. This is distinct from SSRI effects, though the two coexist in treated depression.

Hormonal

Low testosterone: Testosterone modulates the sensitivity of central ejaculatory circuits. Hypogonadism is associated with reduced libido, reduced arousal, and delayed ejaculation. [^corona2011] Testosterone replacement in hypogonadal men with DE often improves ejaculatory function as part of a broader restoration of sexual response.

Hypothyroidism: Thyroid hormone insufficiency affects peripheral nerve conduction velocity and may reduce genital sensory sensitivity.

Diagnosis

History taking is the primary diagnostic tool:

• Onset (lifelong vs acquired)
• Context (generalized vs situational — specifically, can the man ejaculate with masturbation?)
• Medication review (SSRIs, antipsychotics, alpha-blockers, opioids)
• Relationship history and psychosexual history
• Neurological symptoms (urinary dysfunction, extremity neuropathy suggesting diabetic or MS etiology)
• Surgical history (pelvic/retroperitoneal)

Physical examination: focused on neurological testing (bulbocavernosus reflex, perineal sensation) and signs of hypogonadism.

Laboratory: testosterone, TSH, fasting glucose (if diabetic neuropathy suspected).

Treatment

Medication Adjustment

For pharmacologically induced DE, the first step is identifying the causative agent and adjusting if clinically feasible. Options:

• Switching SSRIs (e.g., bupropion does not cause DE and may improve ejaculatory function; mirtazapine has lower ejaculatory side effect rate)
• Dose reduction (if clinically appropriate)
• Switching alpha-blocker class (naftopidil has lower retrograde ejaculation rate than silodosin/tamsulosin)

Testosterone Treatment

In hypogonadal men with DE, testosterone replacement addresses the hormonal deficit. Ejaculatory improvement typically follows libido and arousal improvement rather than being a direct effect. [^corona2011]

Psychosexual Therapy

For situational DE (masturbation but not partner-related), psychosexual approaches have the strongest evidence:

Masturbatory retraining: Graduated modification of masturbation technique toward stimulation that more closely resembles partner sex — reducing idiosyncratic pressure, speed, or grip. The goal is recalibrating the ejaculatory threshold to a broader range of stimuli.

Sensate focus: A structured program of non-goal-oriented touch that removes performance pressure by temporarily prohibiting ejaculation, rebuilding arousal without the anxiety of ejaculatory demand. Paradoxically removing the pressure to ejaculate often resolves the inhibition. [^henry2007]

Partner involvement: Working with the partner to provide more stimulation matching the man's effective pattern during masturbation — incorporating vibration, manual stimulation alongside intercourse, or fantasy.

Pharmacological Treatment

No medications are FDA-approved specifically for DE. Off-label options with variable evidence:

Cabergoline: A dopamine D2/D3 agonist that facilitates ejaculation through central dopaminergic pathways. Case reports and small series show efficacy in SSRI-induced and idiopathic DE. Not suitable for men with cardiac valvulopathy (cabergoline's main safety concern). [^richardson2006]

Cyproheptadine: A serotonin antagonist used to counteract SSRI-induced ejaculatory delay. Typically taken 1–2 hours before sexual activity. Evidence is case series level; response is variable.

Amantadine: Dopaminergic agent with some evidence in SSRI-induced anorgasmia/DE.

Vibrostimulation: For neurogenic anejaculation (spinal cord injury, multiple sclerosis), a penile vibrator applied to the glans/frenulum at high frequency (100 Hz) and amplitude triggers the sacral ejaculatory reflex in men with intact sacral arcs. Success rate of 50–75% in appropriate candidates. Used in spinal cord injury medicine for fertility purposes.

Pelvic Floor Considerations

In men with pelvic floor hypotonicity, the bulbospongiosus and ischiocavernosus muscles may not generate adequate expulsion contractions. Pelvic floor strengthening may improve expulsion phase function. This is less well-studied than for ED but mechanistically plausible given the muscle's role in the expulsion phase.

Differential Diagnosis

Retrograde ejaculation must be distinguished from true DE. In retrograde ejaculation, orgasm occurs but semen enters the bladder rather than exiting antegrade. Diagnosis: post-orgasmic urine specimen showing sperm. Common cause: alpha-blockers, diabetic autonomic neuropathy, bladder neck surgery.

Anejaculation vs anorgasmia: Anejaculation with orgasm (emission failure, expulsion occurs without semen) differs from anorgasmia (no subjective climax). The two have different mechanisms and treatments.

Bottom Line

Delayed ejaculation results from insufficient afferent sensory input to cross the central ejaculatory threshold, or from central inhibition that raises the threshold itself. The most common causes are SSRIs (raising serotonin-mediated inhibition), situational psychological factors (especially idiosyncratic masturbation patterns), and neurological injury. Treatment depends entirely on the cause: medication adjustment for pharmacological DE, masturbatory retraining and sensate focus for psychosexual DE, testosterone for hypogonadal DE, and vibrostimulation or cabergoline for neurogenic or refractory cases.